+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Cluster Headache Market by Treatment Type, Drug Class, Route Of Administration, End User, Distribution Channel, Payer Type - Global Forecast to 2030- Product Image
Cluster Headache Market by Treatment Type, Drug Class, Route Of Administration, End User, Distribution Channel, Payer Type - Global Forecast to 2030- Product Image
Sale

Cluster Headache Market by Treatment Type, Drug Class, Route Of Administration, End User, Distribution Channel, Payer Type - Global Forecast to 2030

  • PDF Icon

    Report

  • 195 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5968098
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Leaders in the healthcare and pharmaceutical sectors face a rapidly evolving cluster headache market, marked by an increased focus on innovative therapies, adaptive manufacturing, and patient-centric access strategies. This report provides strategic clarity and actionable insights to support investment and operational decisions in a highly competitive and regulated landscape.

Market Snapshot: Cluster Headache Market Growth Trajectory

The Cluster Headache Market grew from USD 401.80 million in 2024 to USD 425.19 million in 2025. It is expected to continue growing at a CAGR of 5.77%, reaching USD 562.70 million by 2030.

Scope & Segmentation

This comprehensive analysis covers the full scope of the cluster headache market, offering segmented perspectives and regional intelligence.

  • Treatment Types: Nonpharmaceutical therapies, including behavioral therapy, neuromodulation, and oxygen therapy (with portable, stationary, and inhalation systems), as well as pharmaceutical options like anti-CGRP monoclonal antibodies (Erenumab, Fremanezumab, Galcanezumab), NSAIDs, and triptans (Rizatriptan, Sumatriptan, Zolmitriptan).
  • Drug Classes: Anti-CGRP monoclonal antibodies, NSAIDs, oxygen therapy (delivery systems and inhalation), and triptans.
  • Routes of Administration: Inhalation, nasal, oral, subcutaneous.
  • End Users: Home care, hospitals (emergency and neurology departments), and specialty clinics (headache centers and neurology clinics).
  • Distribution Channels: Hospital, online, retail, and specialty pharmacies.
  • Payer Types: Government reimbursement, out-of-pocket payments, private insurance.
  • Regional Coverage: Americas (United States, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (UK, Germany, France, Russia, Italy, Spain, UAE, Saudi Arabia, South Africa, Denmark, Netherlands, Qatar, Finland, Sweden, Nigeria, Egypt, Turkey, Israel, Norway, Poland, Switzerland), Asia-Pacific (China, India, Japan, Australia, South Korea, Indonesia, Thailand, Philippines, Malaysia, Singapore, Vietnam, Taiwan).
  • Leading Companies: Eli Lilly and Company, H. Lundbeck A/S, Viatris Inc., Teva Pharmaceutical Industries Ltd., AbbVie Inc., Amgen Inc., Novartis AG, Pfizer Inc., Almirall S.A., GlaxoSmithKline plc.

Key Takeaways for Decision-Makers

  • Recognition of cluster headache as a complex neurovascular disorder drives ongoing research and innovation in both pharmaceutical and device-based interventions.
  • Recent therapeutic advances, particularly in neuromodulation and anti-CGRP biologics, are reshaping clinical practice and shifting standard of care toward personalized, preventative treatment strategies.
  • Strategic responses to evolving payer frameworks and value-based reimbursement models emphasize real-world outcomes, cost-effectiveness, and patient adherence.
  • Device innovation and digital health integration are extending care beyond clinical settings, improving treatment adherence and enabling remote patient management.
  • Region-specific dynamics, from infrastructure investment in the Americas to flexible pricing models in fragmented African markets, shape market access strategies and highlight the importance of local adaptation.

Tariff Impact on Supply Chain and Access

  • Implementation of new tariffs in the United States is causing disruptions in the supply chain, increasing production costs for pharmaceutical and device manufacturers.
  • Companies are recalibrating manufacturing footprints, prioritizing domestic and regional production to mitigate tariff exposure and ensure consistent product supply.
  • Payers and insurers are adjusting reimbursement policies, requiring new contracting models and steps to maintain therapy affordability and patient access.

Methodology & Data Sources

Research is grounded in multi-stage methods: in-depth interviews with neurologists, device experts, and payers; comprehensive secondary reviews of clinical literature, regulatory filings, corporate disclosures, and epidemiological databases. Segmentation frameworks and internal validation ensure report accuracy and actionable forecasting.

Why This Report Matters

  • Empowers executives to identify technology trends and competitive moves shaping the cluster headache market landscape.
  • Supports informed decision-making by providing segmentation intelligence, analysis of regulatory shifts, and region-specific strategies.
  • Facilitates effective resource allocation and portfolio planning through deep insights on patient needs, payer dynamics, and channel opportunities.

Conclusion

The cluster headache market is set for further transformation as innovation and evolving care models create new avenues for growth. This report equips decision-makers to navigate risk, optimize investment, and address complex access challenges in a dynamic market.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Cluster Headache Market, by Treatment Type
8.1. Introduction
8.2. Nonpharmaceutical
8.2.1. Behavioral Therapy
8.2.2. Neuromodulation
8.2.3. Oxygen Therapy
8.2.3.1. Delivery Systems
8.2.3.1.1. Portable
8.2.3.1.2. Stationary
8.2.3.2. Inhalation
8.3. Pharmaceutical
8.3.1. Anti-CGRP Monoclonal Antibodies
8.3.1.1. Erenumab
8.3.1.2. Fremanezumab
8.3.1.3. Galcanezumab
8.3.2. NSAIDs
8.3.3. Triptans
8.3.3.1. Rizatriptan
8.3.3.2. Sumatriptan
8.3.3.3. Zolmitriptan
9. Cluster Headache Market, by Drug Class
9.1. Introduction
9.2. Anti-CGRP Monoclonal Antibodies
9.2.1. Erenumab
9.2.2. Fremanezumab
9.2.3. Galcanezumab
9.3. NSAIDs
9.4. Oxygen Therapy
9.4.1. Delivery Systems
9.4.1.1. Portable
9.4.1.2. Stationary
9.4.2. Inhalation
9.5. Triptans
9.5.1. Rizatriptan
9.5.2. Sumatriptan
9.5.3. Zolmitriptan
10. Cluster Headache Market, by Route Of Administration
10.1. Introduction
10.2. Inhalation
10.3. Nasal
10.4. Oral
10.5. Subcutaneous
11. Cluster Headache Market, by End User
11.1. Introduction
11.2. Home Care
11.3. Hospital
11.3.1. Emergency Department
11.3.2. Neurology Department
11.4. Specialty Clinics
11.4.1. Headache Centers
11.4.2. Neurology Clinics
12. Cluster Headache Market, by Distribution Channel
12.1. Introduction
12.2. Hospital Pharmacies
12.3. Online Pharmacies
12.4. Retail Pharmacies
12.5. Specialty Pharmacies
13. Cluster Headache Market, by Payer Type
13.1. Introduction
13.2. Government Reimbursement
13.3. Out-Of-Pocket
13.4. Private Insurance
14. Americas Cluster Headache Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Cluster Headache Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Cluster Headache Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Eli Lilly and Company
17.3.2. H. Lundbeck A/S
17.3.3. Viatris Inc.
17.3.4. Teva Pharmaceutical Industries Ltd.
17.3.5. AbbVie Inc.
17.3.6. Amgen Inc.
17.3.7. Novartis AG
17.3.8. Pfizer Inc.
17.3.9. Almirall S.A.
17.3.10. GlaxoSmithKline plc
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. CLUSTER HEADACHE MARKET MULTI-CURRENCY
FIGURE 2. CLUSTER HEADACHE MARKET MULTI-LANGUAGE
FIGURE 3. CLUSTER HEADACHE MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL CLUSTER HEADACHE MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 10. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 16. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY PAYER TYPE, 2024 VS 2030 (%)
FIGURE 18. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY PAYER TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS CLUSTER HEADACHE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS CLUSTER HEADACHE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES CLUSTER HEADACHE MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES CLUSTER HEADACHE MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA CLUSTER HEADACHE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA CLUSTER HEADACHE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ASIA-PACIFIC CLUSTER HEADACHE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. ASIA-PACIFIC CLUSTER HEADACHE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. CLUSTER HEADACHE MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. CLUSTER HEADACHE MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. CLUSTER HEADACHE MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL CLUSTER HEADACHE MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY NONPHARMACEUTICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY BEHAVIORAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY NEUROMODULATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY OXYGEN THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY DELIVERY SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY PORTABLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY STATIONARY, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY INHALATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY OXYGEN THERAPY, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY NONPHARMACEUTICAL, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY PHARMACEUTICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY ANTI-CGRP MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY ERENUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY FREMANEZUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY GALCANEZUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY ANTI-CGRP MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY NSAIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY TRIPTANS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY RIZATRIPTAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY SUMATRIPTAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY ZOLMITRIPTAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY PHARMACEUTICAL, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY ANTI-CGRP MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY ERENUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY FREMANEZUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY GALCANEZUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY ANTI-CGRP MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY NSAIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY OXYGEN THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY DELIVERY SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY PORTABLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY STATIONARY, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY INHALATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY OXYGEN THERAPY, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY TRIPTANS, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY RIZATRIPTAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY SUMATRIPTAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY ZOLMITRIPTAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY INHALATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY NASAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY HOME CARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY EMERGENCY DEPARTMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY NEUROLOGY DEPARTMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY HOSPITAL, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY HEADACHE CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 63. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY NEUROLOGY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 64. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 65. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 66. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 67. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 68. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 69. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY SPECIALTY PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 70. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY PAYER TYPE, 2018-2030 (USD MILLION)
TABLE 71. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY GOVERNMENT REIMBURSEMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 72. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY OUT-OF-POCKET, BY REGION, 2018-2030 (USD MILLION)
TABLE 73. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY PRIVATE INSURANCE, BY REGION, 2018-2030 (USD MILLION)
TABLE 74. AMERICAS CLUSTER HEADACHE MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 75. AMERICAS CLUSTER HEADACHE MARKET SIZE, BY NONPHARMACEUTICAL, 2018-2030 (USD MILLION)
TABLE 76. AMERICAS CLUSTER HEADACHE MARKET SIZE, BY OXYGEN THERAPY, 2018-2030 (USD MILLION)
TABLE 77. AMERICAS CLUSTER HEADACHE MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2030 (USD MILLION)
TABLE 78. AMERICAS CLUSTER HEADACHE MARKET SIZE, BY PHARMACEUTICAL, 2018-2030 (USD MILLION)
TABLE 79. AMERICAS CLUSTER HEADACHE MARKET SIZE, BY ANTI-CGRP MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 80. AMERICAS CLUSTER HEADACHE MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
TABLE 81. AMERICAS CLUSTER HEADACHE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 82. AMERICAS CLUSTER HEADACHE MARKET SIZE, BY ANTI-CGRP MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 83. AMERICAS CLUSTER HEADACHE MARKET SIZE, BY OXYGEN THERAPY, 2018-2030 (USD MILLION)
TABLE 84. AMERICAS CLUSTER HEADACHE MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2030 (USD MILLION)
TABLE 85. AMERICAS CLUSTER HEADACHE MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
TABLE 86. AMERICAS CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 87. AMERICAS CLUSTER HEADACHE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 88. AMERICAS CLUSTER HEADACHE MARKET SIZE, BY HOSPITAL, 2018-2030 (USD MILLION)
TABLE 89. AMERICAS CLUSTER HEADACHE MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 90. AMERICAS CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 91. AMERICAS CLUSTER HEADACHE MARKET SIZE, BY PAYER TYPE, 2018-2030 (USD MILLION)
TABLE 92. AMERICAS CLUSTER HEADACHE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 93. UNITED STATES CLUSTER HEADACHE MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 94. UNITED STATES CLUSTER HEADACHE MARKET SIZE, BY NONPHARMACEUTICAL, 2018-2030 (USD MILLION)
TABLE 95. UNITED STATES CLUSTER HEADACHE MARKET SIZE, BY OXYGEN THERAPY, 2018-2030 (USD MILLION)
TABLE 96. UNITED STATES CLUSTER HEADACHE MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2030 (USD MILLION)
TABLE 97. UNITED STATES CLUSTER HEADACHE MARKET SIZE, BY PHARMACEUTICAL, 2018-2030 (USD MILLION)
TABLE 98. UNITED STATES CLUSTER HEADACHE MARKET SIZE, BY ANTI-CGRP MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 99. UNITED STATES CLUSTER HEADACHE MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
TABLE 100. UNITED STATES CLUSTER HEADACHE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 101. UNITED STATES CLUSTER HEADACHE MARKET SIZE, BY ANTI-CGRP MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 102. UNITED STATES CLUSTER HEADACHE MARKET SIZE, BY OXYGEN THERAPY, 2018-2030 (USD MILLION)
TABLE 103. UNITED STATES CLUSTER HEADACHE MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2030 (USD MILLION)
TABLE 104. UNITED STATES CLUSTER HEADACHE MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
TABLE 105. UNITED STATES CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 106. UNITED STATES CLUSTER HEADACHE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 107. UNITED STATES CLUSTER HEADACHE MARKET SIZE, BY HOSPITAL, 2018-2030 (USD MILLION)
TABLE 108. UNITED STATES CLUSTER HEADACHE MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 109. UNITED STATES CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 110. UNITED STATES CLUSTER HEADACHE MARKET SIZE, BY PAYER TYPE, 2018-2030 (USD MILLION)
TABLE 111. UNITED STATES CLUSTER HEADACHE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 112. CANADA CLUSTER HEADACHE MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 113. CANADA CLUSTER HEADACHE MARKET SIZE, BY NONPHARMACEUTICAL, 2018-2030 (USD MILLION)
TABLE 114. CANADA CLUSTER HEADACHE MARKET SIZE, BY OXYGEN THERAPY, 2018-2030 (USD MILLION)
TABLE 115. CANADA CLUSTER HEADACHE MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2030 (USD MILLION)
TABLE 116. CANADA CLUSTER HEADACHE MARKET SIZE, BY PHARMACEUTICAL, 2018-2030 (USD MILLION)
TABLE 117. CANADA CLUSTER HEADACHE MARKET SIZE, BY ANTI-CGRP MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 118. CANADA CLUSTER HEADACHE MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
TABLE 119. CANADA CLUSTER HEADACHE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 120. CANADA CLUSTER HEADACHE MARKET SIZE, BY ANTI-CGRP MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 121. CANADA CLUSTER HEADACHE MARKET SIZE, BY OXYGEN THERAPY, 2018-2030 (USD MILLION)
TABLE 122. CANADA CLUSTER HEADACHE MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2030 (USD MILLION)
TABLE 123. CANADA CLUSTER HEADACHE MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
TABLE 124. CANADA CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 125. CANADA CLUSTER HEADACHE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 126. CANADA CLUSTER HEADACHE MARKET SIZE, BY HOSPITAL, 2018-2030 (USD MILLION)
TABLE 127. CANADA CLUSTER HEADACHE MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 128. CANADA CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 129. CANADA CLUSTER HEADACHE MARKET SIZE, BY PAYER TYPE, 2018-2030 (USD MILLION)
TABLE 130. MEXICO CLUSTER HEADACHE MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 131. MEXICO CLUSTER HEADACHE MARKET SIZE, BY NONPHARMACEUTICAL, 2018-2030 (USD MILLION)
TABLE 132. MEXICO CLUSTER HEADACHE MARKET SIZE, BY OXYGEN THERAPY, 2018-2030 (USD MILLION)
TABLE 133. MEXICO CLUSTER HEADACHE MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2030 (USD MILLION)
TABLE 134. MEXICO CLUSTER HEADACHE MARKET SIZE, BY PHARMACEUTICAL, 2018-2030 (USD MILLION)
TABLE 135. MEXICO CLUSTER HEADACHE MARKET SIZE, BY ANTI-CGRP MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 136. MEXICO CLUSTER HEADACHE MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
TABLE 137. MEXICO CLUSTER HEADACHE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 138. MEXICO CLUSTER HEADACHE MARKET SIZE, BY ANTI-CGRP MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 139. MEXICO CLUSTER HEADACHE MARKET SIZE, BY OXYGEN THERAPY, 2018-2030 (USD MILLION)
TABLE 140. MEXICO CLUSTER HEADACHE MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2030 (USD MILLION)
TABLE 141. MEXICO CLUSTER HEADACHE MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
TABLE 142. MEXICO CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 143. MEXICO CLUSTER HEADACHE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 144. MEXICO CLUSTER HEADACHE MARKET SIZE, BY HOSPITAL, 2018-2030 (USD MILLION)
TABLE 145. MEXICO CLUSTER HEADACHE MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 146. MEXICO CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 147. MEXICO CLUSTER HEADACHE MARKET SIZE, BY PAYER TYPE, 2018-2030 (USD MILLION)
TABLE 148. BRAZIL CLUSTER HEADACHE MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 149. BRAZIL CLUSTER HEADACHE MARKET SIZE, BY NONPHARMACEUTICAL, 2018-2030 (USD MILLION)
TABLE 150. BRAZIL CLUSTER HEADACHE MARKET SIZE, BY OXYGEN THERAPY, 2018-2030 (USD MILLION)
TABLE 151. BRAZIL CLUSTER HEADACHE MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2030 (USD MILLION)
TABLE 152. BRAZIL CLUSTER HEADACHE MARKET SIZE, BY PHARMACEUTICAL, 2018-2030 (USD MILLION)
TABLE 153. BRAZIL CLUSTER HEADACHE MARKET SIZE, BY ANTI-CGRP MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 154. BRAZIL CLUSTER HEADACHE MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
TABLE 155. BRAZIL CLUSTER HEADACHE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 156. BRAZIL CLUSTER HEADACHE MARKET SIZE, BY ANTI-CGRP MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 157. BRAZIL CLUSTER HEADACHE MARKET SIZE, BY OXYGEN THERAPY, 2018-2030 (USD MILLION)
TABLE 158. BRAZIL CLUSTER HEADACHE MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2030 (USD MILLION)
TABLE 159. BRAZIL CLUSTER HEADACHE MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
TABLE 160. BRAZIL CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 161. BRAZIL CLUSTER HEADACHE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 162. BRAZIL CLUSTER HEADACHE MARKET SIZE, BY HOSPITAL, 2018-2030 (USD MILLION)
TABLE 163. BRAZIL CLUSTER HEADACHE MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 164. BRAZIL CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 165. BRAZIL CLUSTER HEADACHE MARKET SIZE, BY PAYER TYPE, 2018-2030 (USD MILLION)
TABLE 166. ARGENTINA CLUSTER HEADACHE MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 167. ARGENTINA CLUSTER HEADACHE MARKET SIZE, BY NONPHARMACEUTICAL, 2018-2030 (USD MILLION)
TABLE 168. ARGENTINA CLUSTER HEADACHE MARKET SIZE, BY OXYGEN THERAPY, 2018-2030 (USD MILLION)
TABLE 169. ARGENTINA CLUSTER HEADACHE MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2030 (USD MILLION)
TABLE 170. ARGENTINA CLUSTER HEADACHE MARKET SIZE, BY PHARMACEUTICAL, 2018-2030 (USD MILLION)
TABLE 171. ARGENTINA CLUSTER HEADACHE MARKET SIZE, BY ANTI-CGRP MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 172. ARGENTINA CLUSTER HEADACHE MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
TABLE 173. ARGENTINA CLUSTER HEADACHE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 174. ARGENTINA CLUSTER HEADACHE MARKET SIZE, BY ANTI-CGRP MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 175. ARGENTINA CLUSTER HEADACHE MARKET SIZE, BY OXYGEN THERAPY, 2018-2030 (USD MILLION)
TABLE 176. ARGENTINA CLUSTER HEADACHE MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2030 (USD MILLION)
TABLE 177. ARGENTINA CLUSTER HEADACHE MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
TABLE 178. ARGENTINA CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 179. ARGENTINA CLUSTER HEADACHE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 180. ARGENTINA CLUSTER HEADACHE MARKET SIZE, BY HOSPITAL, 2018-2030 (USD MILLION)
TABLE 181. ARGENTINA CLUSTER HEADACHE MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 182. ARGENTINA CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 183. ARGENTINA CLUSTER HEADACHE MARKET SIZE, BY PAYER TYPE, 2018-2030 (USD MILLION)
TABLE 184. EUROPE, MIDDLE EAST & AFRICA CLUSTER HEADACHE MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 185. EUROPE, MIDDLE EAST & AFRICA CLUSTER HEADACHE MARKET SIZE, BY NONPHARMACEUTICAL, 2018-2030 (USD MILLION)
TABLE 186. EUROPE, MIDDLE EAST & AFRICA CLUSTER HEADACHE MARKET SIZE, BY OXYGEN THERAPY, 2018-2030 (USD MILLION)
TABLE 187. EUROPE, MIDDLE EAST & AFRICA CLUSTER HEADACHE MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2030 (USD MILLION)
TABLE 188. EUROPE, MIDDLE EAST & AFRICA CLUSTER HEADACHE MARKET SIZE, BY PHARMACEUTICAL, 2018-2030 (USD MILLION)
TABLE 189. EUROPE, MIDDLE EAST & AFRICA CLUSTER HEADACHE MARKET SIZE, BY ANTI-CGRP MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 190. EUROPE, MIDDLE EAST & AFRICA CLUSTER HEADACHE MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
TABLE 191. EUROPE, MIDDLE EAST & AFRICA CLUSTER HEADACHE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 192. EUROPE, MIDDLE EAST & AFRICA CLUSTER HEADACHE MARKET SIZE, BY ANTI-CGRP MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 193. EUROPE, MIDDLE EAST & AFRICA CLUSTER HEADACHE MARKET SIZE, BY OXYGEN THERAPY, 2018-2030 (USD MILLION)
TABLE 194. EUROPE, MIDDLE EAST & AFRICA CLUSTER HEADACHE MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2030 (USD MILLION)
TABLE 195. EUROPE, MIDDLE EAST & AFRICA CLUSTER HEADACHE MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
TABLE 196. EUROPE, MIDDLE EAST & AFRICA CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 197. EUROPE, MIDDLE EAST & AFRICA CLUSTER HEADACHE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 198. EUROPE, MIDDLE EAST & AFRICA CLUSTER HEADACHE MARKET SIZE, BY HOSPITAL, 2018-2030 (USD MILLION)
TABLE 199. EUROPE, MIDDLE EAST & AFRICA CLUSTER HEADACHE MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 200. EUROPE, MIDDLE EAST & AFRICA CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 201. EUROPE, MIDDLE EAST & AFRICA CLUSTER HEADACHE MARKET SIZE, BY PAYER TYPE, 2018-2030 (USD MILLION)
TABLE 202. EUROPE, MIDDLE EAST & AFRICA CLUSTER HEADACHE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 203. UNITED KINGDOM CLUSTER HEADACHE MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 204. UNITED KINGDOM CLUSTER HEADACHE MARKET SIZE, BY NONPHARMACEUTICAL, 2018-2030 (USD MILLION)
TABLE 205. UNITED KINGDOM CLUSTER HEADACHE MARKET SIZE, BY OXYGEN THERAPY, 2018-2030 (USD MILLION)
TABLE 206. UNITED KINGDOM CLUSTER HEADACHE MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2030 (USD MILLION)
TABLE 207. UNITED KINGDOM CLUSTER HEADACHE MARKET SIZE, BY PHARMACEUTICAL, 2018-2030 (USD MILLION)
TABLE 208. UNITED KINGDOM CLUSTER HEADACHE MARKET SIZE, BY ANTI-CGRP MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 209. UNITED KINGDOM CLUSTER HEADACHE MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
TABLE 210. UNITED KINGDOM CLUSTER HEADACHE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 211. UNITED KINGDOM CLUSTER HEADACHE MARKET SIZE, BY ANTI-CGRP MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 212. UNITED KINGDOM CLUSTER HEADACHE MARKET SIZE, BY OXYGEN THERAPY, 2018-2030 (USD MILLION)
TABLE 213. UNITED KINGDOM CLUSTER HEADACHE MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2030 (USD MILLION)
TABLE 214. UNITED KINGDOM CLUSTER HEADACHE MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
TABLE 215. UNITED KINGDOM CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 216. UNITED KINGDOM CLUSTER HEADACHE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 217. UNITED KINGDOM CLUSTER HEADACHE MARKET SIZE, BY HOSPITAL, 2018-2030 (USD MILLION)
TABLE 218. UNITED KINGDOM CLUSTER HEADACHE MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 219. UNITED KINGDOM CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 220. UNITED KINGDOM CLUSTER HEADACHE MARKET SIZE, BY PAYER TYPE, 2018-2030 (USD MILLION)
TABLE 221. GERMANY CLUSTER HEADACHE MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 222. GERMANY CLUSTER HEADACHE MARKET SIZE, BY NONPHARMACEUTICAL, 2018-2030 (USD MILLION)
TABLE 223. GERMANY CLUSTER HEADACHE MARKET SIZE, BY OXYGEN THERAPY, 2018-2030 (USD MILLION)
TABLE 224. GERMANY CLUSTER HEADACHE MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2030 (USD MILLION)
TABLE 225. GERMANY CLUSTER HEADACHE MARKET SIZE, BY PHARMACEUTICAL, 2018-2030 (USD MILLION)
TABLE 226. GERMANY CLUSTER HEADACHE MARKET SIZE, BY ANTI-CGRP MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 227. GERMANY CLUSTER HEADACHE MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
TABLE 228. GERMANY CLUSTER HEADACHE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 229. GERMANY CLUSTER HEADACHE MARKET SIZE, BY ANTI-CGRP MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 230. GERMANY CLUSTER HEADACHE MARKET SIZE, BY OXYGEN THERAPY, 2018-2030 (USD MILLION)
TABLE 231. GERMANY CLUSTER HEADACHE MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2030 (USD MILLION)
TABLE 232. GERMANY CLUSTER HEADACHE MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
TABLE 233. GERMANY CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 234. GERMANY CLUSTER HEADACHE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 235. GERMANY CLUSTER HEADACHE MARKET SIZE, BY HOSPITAL, 2018-2030 (USD MILLION)
TABLE 236. GERMANY CLUSTER HEADACHE MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 237. GERMANY CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 238. GERMANY CLUSTER HEADACHE MARKET SIZE, BY PAYER TYPE, 2018-2030 (USD MILLION)
TABLE 239. FRANCE CLUSTER HEADACHE MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 240. FRANCE CLUSTER HEADACHE MARKET SIZE, BY NONPHARMACEUTICAL, 2018-2030 (USD MILLION)
TABLE 241. FRANCE CLUSTER HEADACHE MARKET SIZE, BY OXYGEN THERAPY, 2018-2030 (USD MILLION)
TABLE 242. FRANCE CLUSTER HEADACHE MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2030 (USD MILLION)
TABLE 243. FRANCE CLUSTER HEADACHE MARKET SIZE, BY PHARMACEUTICAL, 2018-2030 (USD MILLION)
TABLE 244. FRANCE CLUSTER HEADACHE MARKET SIZE, BY ANTI-CGRP MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 245. FRANCE CLUSTER HEADACHE MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
TABLE 246. FRANCE CLUSTER HEADACHE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 247. FRANCE CLUSTER HEADACHE MARKET SIZE, BY ANTI-CGRP MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 248. FRANCE CLUSTER HEADACHE MARKET SIZE, BY OXYGEN THERAPY, 2018-2030 (USD MILLION)
TABLE 249. FRANCE CLUSTER HEADACHE MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2030 (USD MILLION)
TABLE 250. FRANCE CLUSTER HEADACHE MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
TABLE 251. FRANCE CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 252. FRANCE CLUSTER HEADACHE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 253. FRANCE CLUSTER HEADACHE MARKET SIZE, BY HOSPITAL, 2018-2030 (USD MILLION)
TABLE 254. FRANCE CLUSTER HEADACHE MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 255. FRANCE CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 256. FRANCE CLUSTER HEADACHE MARKET SIZE, BY PAYER TYPE, 2018-2030 (USD MILLION)
TABLE 257. RUSSIA CLUSTER HEADACHE MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 258. RUSSIA CLUSTER HEADACHE MARKET SIZE, BY NONPHARMACEUTICAL, 2018-2030 (USD MILLION)
TABLE 259. RUSSIA CLUSTER HEADACHE MARKET SIZE, BY OXYGEN THERAPY, 2018-2030 (USD MILLION)
TABLE 260. RUSSIA CLUSTER HEADACHE MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2030 (USD MILLION)
TABLE 261. RUSSIA CLUSTER HEADACHE MARKET SIZE, BY PHARMACEUTICAL, 2018-2030 (USD MILLION)
TABLE 262. RUSSIA CLUSTER HEADACHE MARKET SIZE, BY ANTI-CGRP MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 263. RUSSIA CLUSTER HEADACHE MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
TABLE 264. RUSSIA CLUSTER HEADACHE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 265. RUSSIA CLUSTER HEADACHE MARKET SIZE, BY ANTI-CGRP MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 266. RUSSIA CLUSTER HEADACHE MARKET SIZE, BY OXYGEN THERAPY, 2018-2030 (USD MILLION)
TABLE 267. RUSSIA CLUSTER HEADACHE MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2030 (USD MILLION)
TABLE 268. RUSSIA CLUSTER HEADACHE MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
TABLE 269. RUSSIA CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 270. RUSSIA CLUSTER HEADACHE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 271. RUSSIA CLUSTER HEADACHE MARKET SIZE, BY HOSPITAL, 2018-2030 (USD MILLION)
TABLE 272. RUSSIA CLUSTER HEADACHE MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 273. RUSSIA CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 274. RUSSIA CLUSTER HEADACHE MARKET SIZE, BY PAYER TYPE, 2018-2030 (USD MILLION)
TABLE 275. ITALY CLUSTER HEADACHE MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 276. ITALY CLUSTER HEADACHE MARKET SIZE, BY NONPHARMACEUTICAL, 2018-2030 (USD MILLION)
TABLE 277. ITALY CLUSTER HEADACHE MARKET SIZE, BY OXYGEN THERAPY, 2018-2030 (USD MILLION)
TABLE 278. ITALY CLUSTER HEADACHE MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2030 (USD MILLION)
TABLE 279. ITALY CLUSTER HEADACHE MARKET SIZE, BY PHARMACEUTICAL, 2018-2030 (USD MILLION)
TABLE 280. ITALY CLUSTER HEADACHE MARKET SIZE, BY ANTI-CGRP MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 281. ITALY CLUSTER HEADACHE MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
TABLE 282. ITALY CLUSTER HEADACHE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 283. ITALY CLUSTER HEADACHE MARKET SIZE, BY ANTI-CGRP MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 284. ITALY CLUSTER HEADACHE MARKET SIZE, BY OXYGEN THERAPY, 2018-2030 (USD MILLION)
TABLE 285. ITALY CLUSTER HEADACHE MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2030 (USD MILLION)
TABLE 286. ITALY CLUSTER HEADACHE MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
TABLE 287. ITALY CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 288. ITALY CLUSTER HEADACHE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 289. ITALY CLUSTER HEADACHE MARKET SIZE, BY HOSPITAL, 2018-2030 (USD MILLION)
TABLE 290. ITALY CLUSTER HEADACHE MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 291. ITALY CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 292. ITALY CLUSTER HEADACHE MARKET SIZE, BY PAYER TYPE, 2018-2030 (USD MILLION)
TABLE 293. SPAIN CLUSTER HEADACHE MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 294. SPAIN CLUSTER HEADACHE MARKET SIZE, BY NONPHARMACEUTICAL, 2018-2030 (USD MILLION)
TABLE 295. SPAIN CLUSTER HEADACHE MARKET SIZE, BY OXYGEN THERAPY, 2018-2030 (USD MILLION)
TABLE 296. SPAIN CLUSTER HEADACHE MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2030 (USD MILLION)
TABLE 297. SPAIN CLUSTER HEADACHE MARKET SIZE, BY PHARMACEUTICAL, 2018-2030 (USD MILLION)
TABLE 298. SPAIN CLUSTER HEADACHE MARKET SIZE, BY ANTI-CGRP MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 299. SPAIN CLUSTER HEADACHE MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
TABLE 300. SPAIN CLUSTER HEADACHE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 301. SPAIN CLUSTER HEADACHE MARKET SIZE, BY ANTI-CGRP MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 302. SPAIN CLUSTER HEADACHE MARKET SIZE, BY OXYGEN THERAPY, 2018-2030 (USD MILLION)
TABLE 303. SPAIN CLUSTER HEADACHE MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2030 (USD MILLION)
TABLE 304. SPAIN CLUSTER HEADACHE MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
TABLE 305. SPAIN CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 306. SPAIN CLUSTER HEADACHE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 307. SPAIN CLUSTER HEADACHE MARKET SIZE, BY HOSPITAL, 2018-2030 (USD MILLION)
TABLE 308. SPAIN CLUSTER HEADACHE MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 309. SPAIN CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 310. SPAIN CLUSTER HEADACHE MARKET SIZE, BY PAYER TYPE, 2018-2030 (USD MILLION)
TABLE 311. UNITED ARAB EMIRATES CLUSTER HEADACHE MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 312. UNITED ARAB EMIRATES CLUSTER HEADACHE MARKET SIZE, BY NONPHARMACEUTICAL, 2018-2030 (USD MILLION)
TABLE 313. UNITED ARAB EMIRATES CLUSTER HEADACHE MARKET SIZE, BY OXYGEN THERAPY, 2018-2030 (USD MILLION)
TABLE 314. UNITED ARAB EMIRATES CLUSTER HEADACHE MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2030 (USD MILLION)
TABLE 315. UNITED ARAB EMIRATES CLUSTER HEADACHE MARKET SIZE, BY PHARMACEUTICAL, 2018-2030 (USD MILLION)
TABLE 316. UNITED ARAB EMIRATES CLUSTER HEADACHE MARKET SIZE, BY ANTI-CGRP MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 317. UNITED ARAB EMIRATES CLUSTER HEADACHE MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
TABLE 318. UNITED ARAB EMIRATES CLUSTER HEADACHE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 319. UNITED ARAB EMIRATES CLUSTER HEADACHE MARKET SIZE, BY ANTI-CGRP MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 320. UNITED ARAB EMIRATES CLUSTER HEADACHE MARKET SIZE, BY OXYGEN THERAPY, 2018-2030 (USD MILLION)
TABLE 321. UNITED ARAB EMIRATES CLUSTER HEADACHE MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2030 (USD MILLION)
TABLE 322. UNITED ARAB EMIRATES CLUSTER HEADACHE MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
TABLE 323. UNITED ARAB EMIRATES CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 324. UNITED ARAB EMIRATES CLUSTER HEADACHE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 325. UNITED ARAB EMIRATES CLUSTER HEADACHE MARKET SIZE, BY HOSPITAL, 2018-2030 (USD MILLION)
TABLE 326. UNITED ARAB EMIRATES CLUSTER HEADACHE MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 327. UNITED ARAB EMIRATES CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 328. UNITED ARAB EMIRATES CLUSTER HEADACHE MARKET SIZE, BY PAYER TYPE, 2018-2030 (USD MILLION)
TABLE 329. SAUDI ARABIA CLUSTER HEADACHE MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 330. SAUDI ARABIA CLUSTER HEADACHE MARKET SIZE, BY NONPHARMACEUTICAL, 2018-2030 (USD MILLION)
TABLE 331. SAUDI ARABIA CLUSTER HEADACHE MARKET SIZE, BY OXYGEN THERAPY, 2018-2030 (USD MILLION)
TABLE 332. SAUDI ARABIA CLUSTER HEADACHE MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2030 (USD MILLION)
TABLE 333. SAUDI ARABIA CLUSTER HEADACHE MARKET SIZE, BY PHARMACEUTICAL, 2018-2030 (USD MILLION)
TABLE 334. SAUDI ARABIA CLUSTER HEADACHE MARKET SIZE, BY ANTI-CGRP MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 335. SAUDI ARABIA CLUSTER HEADACHE MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
TABLE 336. SAUDI ARABIA CLUSTER HEADACHE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 337. SAUDI ARABIA CLUSTER HEADACHE MARKET SIZE, BY ANTI-CGRP MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 338. SAUDI ARABIA CLUSTER HEADACHE MARKET SIZE, BY OXYGEN THERAPY, 2018-2030 (USD MILLION)
TABLE 339. SAUDI ARABIA CLUSTER HEADACHE MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2030 (USD MILLION)
TABLE 340. SAUDI ARABIA CLUSTER HEADACHE MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
TABLE 341. SAUDI

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Cluster Headache market report include:
  • Eli Lilly and Company
  • H. Lundbeck A/S
  • Viatris Inc.
  • Teva Pharmaceutical Industries Ltd.
  • AbbVie Inc.
  • Amgen Inc.
  • Novartis AG
  • Pfizer Inc.
  • Almirall S.A.
  • GlaxoSmithKline plc

Table Information

Report AttributeDetails
No. of Pages195
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 425.19 Million
Forecasted Market Value ( USD ) by 2030 $ 562.7 Million
Compound Annual Growth Rate5.7%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Cluster Headache - Pipeline Insight, 2025 - Product Image

Cluster Headache - Pipeline Insight, 2025

  • Drug Pipelines
  • 60 Pages
  • Global
From
Cluster Headache Syndrome- Pipeline Insight, 2025 - Product Image

Cluster Headache Syndrome- Pipeline Insight, 2025

  • Clinical Trials
  • 60 Pages
  • Global
From
Post-Traumatic Headache Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Post-Traumatic Headache Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From
Migraine Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Migraine Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 185 Pages
  • Global
From
India Paracetamol Market, By Region, Competition, Forecast & Opportunities, 2020-2030F - Product Image

India Paracetamol Market, By Region, Competition, Forecast & Opportunities, 2020-2030F

  • Report
  • 85 Pages
  • India
From

About the Market

Cluster Headache Syndrome (CHS) is a rare neurological disorder characterized by severe, debilitating headaches. It is estimated to affect approximately 0.1% of the population. Treatment for CHS is typically divided into two categories: acute and preventive. Acute treatments are used to provide immediate relief from the pain of a cluster headache attack, while preventive treatments are used to reduce the frequency and severity of attacks. The Cluster Headache Syndrome Drug market is a subset of the Central Nervous System Drugs market. It is composed of pharmaceuticals used to treat CHS, including triptans, ergot alkaloids, and corticosteroids. These drugs are typically administered orally, intranasally, or subcutaneously. The Cluster Headache Syndrome Drug market is highly competitive, with many large pharmaceutical companies vying for market share. Some of the major players in the market include GlaxoSmithKline, Pfizer, Novartis, Merck, and Sanofi. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.